Feasibility of alternate-day chemotherapy with S-1 for adjuvant chemotherapy in elderly patients with locally head and neck cancer

Feasibility of alternate-day chemotherapy with S-1 for adjuvant chemotherapy in elderly patients with locally head and neck cancer - Feasibility of alternate-day chemotherapy with S-1 for adjuvant chemotherapy in elderly patients with locally head and neck cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013279

Enrollment

Registered

2014-02-28

Start date

2014-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

S-1 is administered orally at 80-120mg/body for monday wednesday friday sunday,duplicate for 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)CR decision within 3 month 2)histologically confirmed squamous cell carcinoma 3)primary lesion is maxillary sinus,oral cabity,oropharynx,hypopharynx,larynx(exclude glottisT3No) 4)pStage3,4A,3B 5initial treatment is CR 6)PS0-1 7)with ability of oral intake 8)suffcient function of important organs a)WBC:3,000/mm3-12,000mm3 b)NEU:over2,000/mm3 c)PLT:over100,000mm3 d)Hb:over9.9g/dl e)T-Bil:under1.5mg/dl f)AST,ALT:under100IU/l g)Ccr:over50mL/min 9)written informed consent

Exclusion criteria

Exclusion criteria: 1)administration contraindication for testing drugs 2)receiving flucytocine,phenytoin,warfarin 3)with infection which need to treat 4)with interstitial pneumonitis 5)with severe complications 6)with diarrhea 7)pregnant or nursing woman or women who like be pregnant and men with partner willing to get pregnant 8)doctor's decision not to be registered to this study

Design outcomes

Primary

Measure	Time frame
feasibility	—

Secondary

Measure	Time frame
safety,progression free survival,overall survival	—

Countries

Japan

Contacts

Public Contactkazunori Fujiwara

Tottori University Hospital Division of Otolarygology,Head and Neck Surgery

kfujiwa@grape.med.tottori-u.ac.jp0859-38-6627

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026